Background/Aims: Chronic inflammation contributes to the development of type 2 diabetes mellitus by targeting the insulin receptor substrate protein-1 (IRS-1) signaling pathway. Previous studies showed that Leukemia related protein 16 (LRP16) reduced insulin stimulated glucose uptake in adipocytes by impairing the IRS-1 signaling pathway. We explored the mechanism by which LRP16 promotes the inflammatory response. Methods: We screened LRP16 induced proteins in the lipopolysaccharide (LPS)-stimulated inflammatory response using liquid chromatography-mass spectrometry (LC-MS) and analyzed the potential biological functions of these proteins using online bioinformatics tools. mRNA expression and protein expression of target genes were measured by real time PCR and Western blot, respectively. Results: A total of 390 differentially expressed proteins were identified. The mitogen-activated protein kinase (MAPK) signaling pathway was the primary activated pathway in LRP16-expressing cells. Overexpression of LRP16 activated ERK1/2 and Rac1, which are two key players related to the MAPK signaling pathway. Furthermore, knock down of endogenous LRP16 by RNA interference (RNAi) reduced Rac1 expression, ERK activation, and inflammatory cytokine expression in human adipocytes stimulated by LPS. The stimulatory effect of LRP16 was diminished by suppressing Rac1 expression and treating the cells with the ERK specific inhibitor, PD98059. Conclusion: These findings revealed the functions of LRP16 in promoting the inflammatory response through activating the Rac1-MAPK1/ERK pathway in human adipocytes.
MACROD1/LRP16 Enhances LPS-Stimulated

Introduction
Leukemia related protein 16 (LRP16), also known as MACRO domain containing 1 (MACROD1), is a co-activator of estrogen receptor alpha (ERα). LRP16 was first cloned from acute myeloid leukemia cells in our laboratory [1] . Ma et al., showed that LRP16 expression gradually increased during 3T3-L1 preadipocyte differentiation, suggesting that LRP16 plays a crucial role in adipocyte maturation [2] . LRP16 expression has been found both in the cytosol and nucleus ,and nuclear LRP16 plays different biological actions [3] . LRP16 is considered a crucial regulator of the transcription factor nuclear factor κB (NF-κB) because it integrates into its transcriptional complex [4] . LRP16 was identified as a negative regulator of insulin through impairing the insulin receptor substrate protein-1 (IRS-1) signaling pathway [5] . However, the mechanism by which LRP16 impairs the IRS-1 signaling pathway is still poorly understood.
One of the earliest etiological factors of type 2 diabetes mellitus is the development of peripheral insulin resistance, which is caused by abnormalities in the IRS-1 signaling pathway [6] . Previous in vitro and in vivo evidence suggests that chronic inflammation contributes to the pathogenesis of diabetes mellitus by inhibiting IRS-1 signaling [7] and by modulating inflammatory cytokines such as tumor necrosis factor alpha (TNFα), interleukin-1 (IL-1) and IL-6 [8] . As a pivotal molecule, NF-κB has been shown to induce insulin resistance in multiple organs (fat, muscle and liver) [9, 10] . Both NF-κB and mitogen activated protein kinase (MAPK) signaling pathways contribute to adipocyte inflammation [11] . Therefore, developing anti-inflammatory targets is a reasonable strategy to treat type 2 diabetes mellitus. Protein screening and validation can provide important information about LRP16-mediated inflammation in adipocytes. Considering that insulin resistance induced by chronic mild inflammation widely occurs in human visceral fat tissue, we used human preadipocytevisceral (HPA-v) cells in this study.
Materials and Methods
Reagents
The LRP16 plasmid was described in our previous reports [12] . LRP16 and Rac1 specific siRNA were chemically synthesized by GenChem Co (Shanghai, China). LPS was purchased from Sigma Aldrich (St. Louis, Missouri, USA). The ERK specific inhibitor, PD98059, was obtained from New England Biolabs. DMEM and fetal bovine serum (FBS) were obtained from Gibco (Paisley, USA). Lipofectamine 2000 was purchased from Invitrogen. SuperFect transfection reagent was obtained from QIAGEN. Dexamethasone was obtained from Steraloids. Insulin, indomethacin, isobutylmethylxanthine, and peroxisome proliferator-activated receptor (PPAR) agonist were purchased from Sigma Aldrich. Rabbit anti-Rac1 antibody was purchased from Sigma Aldrich. Rabbit antibodies against TNFα, c-Jun, c-fos, NF-κB, p65, IL-1β, IL-2, IL-4, IL-6, and phosphorylated (p)-ERK1/2 were purchased from Abcam (Cambridge, Massachusetts, USA). Goat anti-rabbit IgG horse radish peroxidase (HRP)-conjugated secondary antibodies were purchased from Cell Signaling Technology (Beverly, Massachusetts, USA).
Cell culture, cell transfection and cell differentiation HPA-v cells were originally obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in DMEM culture medium supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 U/mL streptomycin. Plasmid encoding LRP16 or the empty vector pcDNA3.1 (control) was transfected into the human preadipocytes using SuperFect reagent. Cells stably expressing LRP16 or empty control vector were screened by incubating cells in culture medium supplemented with 0.4 μg/mL G418. LRP16, Rac1 specific siRNA or siRNA negative control was transfected into the cells using Lipofectamine 2000 according to the manufacturer's recommendations. Differentiation of wide-type human preadipocytes into mature adipocytes was previously reported [13] . Briefly, cells were maintained in culture medium containing dexamethasone (0.5 μM), insulin (5 μg/mL), indomethacin (100 μM), isobutylmethylxanthine (0.25 mM), and PPAR agonist (100 μM) for two weeks to induce differentiation. Protein preparation Mature adipocytes transfected with plasmid encoding LRP16 and control cells were lysed in protein lysis buffer containing 1% NP-40, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 50 mM pH 7.6 TrisHCl, 0.5% deoxycholic acid, 1 μg/mL aprotinin,1 μg/mL leupeptin, and 0.5 mM phenylmethylsulfonyl fluoride. After a 30 min incubation on ice, samples were centrifuged at 12, 000 r/min for 30 min at 4°C. The supernatant was collected and protein concentration was determined by the bicinchoninic acid (BCA) method (Bio-Rad, Hercules, CA, USA). A total of 100 μg protein was incubated with 10 mM DTT at 56°C for 1 h, followed by alkalization by 50 mM iodoacetamide (IAM) for 45 min. After diluting with 25 mM NH 4 HCO 3 , protein samples were digested with 1% trypsin at 37°C and digestion was terminated with 0.1% formic acid (FA). After centrifuging at 13, 000 r/min for 10 min, the supernatant was collected and stored at -80°C until MS analysis.
LC-MS analysis
The multidimensional protein identification device is composed of an LTQ-ion trap (Thermo Fisher Scientific, Waltham, USA) mass spectrometer with an electrospray ionization (nano-ESI) source. Highthroughput liquid chromatography-mass spectrometry (LC-MS) analysis was performed as previously described [14] [15] [16] . In brief, 100 μg of peptides were loaded onto a biphasic capillary column by highpressure nitrogen. The mobile phase consisted of solution A (5% AN, 0.1% FA), solution B (80% AN, 0.1% FA), and solution C (800 mM ammonium acetate, 5% AN, 0.1% FA). For MS analysis, the elution from the column was loaded onto a C18 analytical capillary chromatography column and a fraction from the column was ionized by electrospray, with a spray voltage of 2.0 kV and at 200°C. Data-dependent acquisition mode was applied for MS data collection. XCalibur (Thermo Fisher Scientific, Waltham, USA) was used to control the elution gradient of high performance liquid chromatography (HPLC) and MS scanning.
Data analysis and protein functional groupings
LC-MS data were processed using Progenesis LC-MS software (Nonlinear Dynamics Corp, Newcastle upon Tyne, UK) using the default settings. The NCBI human database (March 2011) was applied for protein identification. The RefSeq of proteins was transformed into UniProtKB at: http://www.uniprot.org [17] . Differentially expressed proteins were analyzed according to the Gene Ontology (GO) classification. Pathway networks and protein functional grouping were generated using the online platform according to the pathway-biocarta and pathway-kegg analyses: http://bioinfo.capitalbio.com/mas.
Real-time PCR assay
Mature adipocytes over-expressing LRP16, LRP16 and Rac1 knock down cells, and their wide-type control cells were plated into 60-mm diameter dishes. The cells were stimulated with LPS (120 ng/ml) for 40 min, treated with the ERK inhibitor, PD98059 (100 ng/ml), and collected. The TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) was used for total RNA isolation. Isolated RNA was reverse transcribed into cDNA using M-MLV reverse transcriptase (1 to 2 μg) (Invitrogen). Real-time quantitative PCR was carried out using a Taq-Man PCR Master Mix and an ICycler system (Bio-Rad). The relative expression of gene (fold-change vs. control) was calculated by the 2 -ΔΔCt method [18] . Data were quantified from three independent experiments.
Western blot assay
A total of 50 μg protein was separated by 7.5% SDS-PAGE. After electrophoresis, proteins were transferred to a PVDF membrane, blocked with 5% skim milk, and incubated with primary antibodies for 2 h at room temperature. Subsequently, membranes were probed with horseradish peroxidase (HRP)-conjugated secondary antibodies. Immunoreactivity was visualized with a super enhanced chemiluminescent (ECL) detection reagent (Shanghai Yeasen Biological Technology, China). Glyceraldehyde phosphate dehydrogenase (GAPDH) was used as an internal loading control. The relative expression of target protein was normalized to GAPDH.
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Statistical analysis Data analysis was performed using SPSS 13.0 (SPSS Inc, Chicago, IL, USA) software. The results were expressed as means ± standard deviation (SD). Statistical analysis of two groups was performed using individual Student's t tests, and statistical analysis of more than two groups was performed using one-way analysis of variance (ANOVA) followed by a Tukey's post hoc test or two-way ANOVA followed by Bonferroni post. A P value < 0.05 was considered statistically significant.
Results
LC-MS analysis
HPA-v cells stably transfected with plasmid encoding LRP16 showed a 2-fold increase in LRP16 expression compared to control (Fig. 1A) . 1, 075 total proteins and 390 differentially expressed proteins were identified in the cells stably overexpressing LRP16 relative to the control cells. The top 30 differentially expressed proteins are listed in Table 1 . According to the LC-MS analysis criteria, the proteins with 20 > ratio > 1.5 were considered up-regulated, while proteins with 0.05 < ratio < 0.66 were considered down-regulated. Of all the differently expressed proteins, one protein was absent in the Uniprot database (accession No is AF202922_1).
Functional grouping of differentially expressed proteins
Among these proteins, 353 are related to cellular component, 303 to molecular functions, 337 to biological processes, and 93 to enzyme (Fig. 2A) . The subgroup analysis is as follows: (1) proteins related to cell component include cell part, organelle part, membrane and macromolecular complex; (2) proteins related to molecular function include binding, catalytic activity, structural molecule activity and transporter activity; and (3) in the biological process category, most proteins (304) are relevant to cellular processes and other biological processes including biological regulation, single-organism process, response to stimulus, cellular component organization, or biogenesis ( Fig. 2B-D) .
Pathway analysis
Significant pathways were identified by analyzing differentially expressed proteins (Tables 2-4 ). The major pathways identified by the pathway-biocarta analysis were transcription factor cAMP-response element binding protein (CREB) and its extracellular signals, electron transport reaction in mitochondria, eukaryotic protein translation, and how progesterone initiates oocyte membrane. The major pathways identified by the pathway-KEGG analysis were ribosome, Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, oxidative phosphorylation and MAPK signaling pathway. By analyzing the relationship between these pathways and differentiated genes, MAPK1 (ERK) and Rac1 were repeatedly found to be involved in the same pathways. 
MAPK and Rac1 protein analysis
We analyzed protein interaction using the Molecular Annotation System (MAS) (pathway-biocarta networks and pathway-KEGG networks of all proteins). MAPK was found to interact with many other proteins. The MAPK pathway-biocarta networks showed that MAPK can interact with Rac1. The MAPK pathway-KEGG networks also suggested that MAPK can interact with Rac1. Activation of the MAPK signaling pathway has been reported in diabetic rats [19] . In addition, the MAPK signaling pathway is involved in inflammation and cell apoptosis caused by chronic intermittent hypoxia in rat pancreatic tissues [20] . MAPK signaling also contributes to the inflammatory response in adipocytes [11] . Based on these findings, we hypothesized that the Rac1/MAPK1 signaling pathway plays a role in the LRP16-mediated inflammatory response in adipocytes. MAPK signaling pathway related proteins are shown in Table 5 . 
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To verify the influence of LRP16 on MAPK1 and Rac1 protein expression, we analyzed protein expression of Rac1, phosphorylated ERK1/2 and downstream genes (e.g. TNFα, c-Jun, c-fos, p65, IL-1β, IL-2, IL-4, IL-6) in LRP16 over-expressing or silenced cells in response to LPS. LRP16 overexpression significantly increased p-ERK1/2 expression and its downstream genes following LPS stimulation (Fig. 3C) . Transfection of siRNA targeting LRP16 efficiently reduced LRP16 expression in cells (Fig. 1B) . We also demonstrated that siRNA mediated knock down of LRP16 attenuated p-ERK1/2 expression and reduced expression of downstream genes (Fig. 3D) . Consistent with the increase in p-ERK1/2, overexpression of LRP16 increased Rac1 expression, which was further supported by the loss-of-function experiment using siRNA-LRP16 (Fig. 3C-D) .
Consistent with the western blot results, LRP16 also induced mRNA expression of ERK downstream genes, c-Jun, c-fos, p65, and inflammatory cytokines (e.g. TNFα, IL-1β, IL-2, IL-4, IL-6), and siRNA mediated knock down of LRP16 attenuated the expression of these genes (Fig. 4) .
Rac1 is required for LRP16-induced ERK1/2 phosphorylation
To determine whether LRP16-induced ERK1/2 phosphorylation is mediated by Rac1, we examined ERK1/2 phosphorylation in siRNARac1 expressing human adipocytes. As expected, overexpression of LRP16 stimulated p-ERK1/2 and its downstream genes following LPS stimulation. However, this effect was markedly diminished in the Rac1-knock down cells indicating that Rac1 is required for LRP16 induced ERK1/2 phosphorylation (Fig. 5) . 
ERK is required for LRP16 regulation of the inflammatory response in human adipocytes
Given that ERK1/2 phosphorylation was induced by LRP16, we next asked whether pharmacological inhibition of ERK1/2 alters regulation of its downstream genes and informatory factors in LRP16 expressing adipocytes. LRP16 expressing adipocytes exposed to PD98059, a pharmacological inhibitor of ERK, reduced mRNA and protein expression of c-fos, p65, c-Jun, and inflammatory factors TNFα, IL-1β, IL-2, IL-4 and IL-6 compared to widetype control cells. However, PD98059 had no significant effect on Rac1 mRNA and protein expression (Fig. 6) . 
Discussion
We identified 390 differentially expressed proteins in LRP16 over-expressing human adipocytes. Among these proteins, we identified MAPK1 and Rac1, which are related to the MAPK signaling pathway. Using gain-of-function and loss-of-function assays we revealed a novel function of LRP16: LRP16 stimulates the inflammatory response through a Rac1 and ERK1/2 dependent pathway.
Previous studies suggested that insulin resistance is associated with chronic inflammation, and several mediators, including pro-inflammatory cytokines and adipocytokines, released from adipocytes have been identified as factors involved in the development of type 2 diabetes mellitus [7] . The pro-inflammatory cytokines include TNFα, IL-1β, IL-6, and various adipocytokines [21, 22] . As a crucial signaling pathway to regulate inflammatory response, NF-κB as well as several other transcription factors and kinases are involved in this process [7] . IRS-1 signaling plays an essential role in chronic inflammation associated with type 2 diabetes mellitus. This pathway is activated by tyrosine phosphorylation of IRS-1. LRP16 was identified as a negative regulator of insulin through impairing the IRS-1 signaling pathway [23] , but the mechanism by which LRP16 impairs IRS-1 signaling is largely unknown. LRP16 was reported to be a crucial regulator of NF-κB, which causes insulin resistance through altering tyrosine phosphorylation of IRS-1 [4] . Given the putative role of NF-κB in regulating the chronic inflammatory response, we speculate that LRP16 disrupts the IRS-1 pathway in the chronic inflammatory response. LC-MS screening identified 390 differentially expressed proteins in the mature adipocytes stably transfected with plasmid encoding LRP16 and control cells. MAPK1 and Rac1 protein expression increased with overexpression of LRP16. Furthermore, our analyses indicated that MAPK1 and Rac1 can interact with each other. Pathway analyses indicated that MAPK and Rac1 share a similar profile in terms of involved pathways. ERK, a constitutive component of the MAPK1 family, has been shown to regulate the inflammatory response in adipocytes [24, 25] . The LC-MS profiling results led us to investigate the possible roles of ERK and Rac1 in the LRP16 mediated inflammatory response in human adipocytes.
As a member of the MAPK1 family, phosphorylated ERKl/2 translocates from the cytoplasm to the nucleus and participates in the inflammatory response by activating NF-κB, AP-1, c-fos, and c-Jun [26, 27] . Ectopic expression of LRP16 induced phosphorylation of ERK1/2, and expression of Rac1, transcription factors (c-fos, p65, and c-Jun), and inflammatory cytokines (TNFα, IL-1β, IL-2, IL-4, IL-6). Importantly, knock down of LRP16 reduced expression of these ERK mediated downstream genes and cytokines, indicating that LRP16 is required for the inflammatory response in human adipocytes. We further demonstrated that the stimulatory effect of LRP16 on the inflammatory response was markedly diminished by knock down of Rac1 and inhibiting the function of ERK1/2 with the chemical inhibitor, PD98059. Inhibiting ERK1/2 reduced expression of transcription factors and inflammatory cytokines. Overall, we uncovered a novel signaling pathway in adipocytes: LRP16 regulates the inflammatory response in LPS-stimulated human adipocytes via a Rac1 and ERK1/2-dependent pathway. However, it should also be noted that we did not measure specific changes in ERK1 or ERK2 mRNA and protein expression in response to LPS and/ or LRP16 in this current study. Therefore, we could not determine the involvement of the specific ERK subtype based on the present data.
Previously we showed that LRP16 induced insulin resistance in adipocytes and skeletal muscle cells by impairing the IRS-1 signaling pathway and peroxisome proliferator-activated receptor-γ (PPARγ) activity, respectively [23, 28] . In combination with the results from the current study, we have a better understanding of the role LRP16 plays in the inflammation regulatory network and clarified the exact roles of the NF-κB and Rac1-MAPK1/ERK signaling pathways in the inflammatory response.
Conclusion
In summary, we show that LRP16 promotes the inflammatory response through modulating Rac1 and activating ERK1/2. Our conclusion is based on pathway analysis and screening results from LC-MS profiling using LRP16 expressing human adipocytes. These findings uncover a novel mechanism of LRP16-mediated inflammation in type 2 diabetes mellitus. However, our in vitro findings have not yet been validated physiologically. Further in vivo studies and clinical data are required to explore the clinical significance of this pathway.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry
